Michael Truett Tate - 17 Feb 2026 Form 4 Insider Report for Astera Labs, Inc. (ALAB)

Signature
/s/ Philip Mazzara, Attorney-in-Fact
Issuer symbol
ALAB
Transactions as of
17 Feb 2026
Net transactions value
-$1,485,784
Form type
4
Filing time
19 Feb 2026, 20:52:16 UTC
Previous filing
10 Feb 2026

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Tate Michael Truett Chief Financial Officer C/O ASTERA LABS, INC., 2345 NORTH FIRST STREET, SAN JOSE /s/ Philip Mazzara, Attorney-in-Fact 19 Feb 2026 0001399546

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ALAB Common Stock Sale $91,984 -753 -0.37% $122.16 203,331 17 Feb 2026 Direct F1, F2
transaction ALAB Common Stock Sale $522,086 -4,250 -2.1% $122.84 199,081 17 Feb 2026 Direct F1, F3
transaction ALAB Common Stock Sale $440,690 -3,556 -1.8% $123.93 195,525 17 Feb 2026 Direct F1, F4
transaction ALAB Common Stock Sale $284,343 -2,281 -1.2% $124.66 193,244 17 Feb 2026 Direct F1, F5
transaction ALAB Common Stock Sale $146,681 -1,161 -0.6% $126.34 192,083 17 Feb 2026 Direct F1
holding ALAB Common Stock 450,281 17 Feb 2026 By Tate Trust F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares of the Issuer's Common Stock required to be sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting and settlement of restricted stock units previously granted to the Reporting Person. Such sales were automatic and mandated by an election of the Issuer made in advance of the vesting event to require the satisfaction of tax withholding obligations to be funded by a "sell to cover", and does not represent a discretionary trade by the Reporting Person.
F2 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $122.1000 to $122.2800, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $122.3200 to $123.3000, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $123.3300 to $124.3200, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $124.3500 to $125.3200, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F6 These shares are owned directly by the Tate 1997 Living Trust Dated April 24, 1997 (the "Tate Trust"), of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of these securities, except to the extent, if any, of his pecuniary interest therein, and the filing of this Form 4 is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.